197 related articles for article (PubMed ID: 37173959)
21. Abrogation of USP9X Is a Potential Strategy to Decrease PEG10 Levels and Impede Tumor Progression in Cutaneous T-Cell Lymphoma.
Xiong S; Liu F; Sun J; Gao S; Wong CCL; Tu P; Wang Y
J Invest Dermatol; 2024 Apr; ():. PubMed ID: 38677662
[TBL] [Abstract][Full Text] [Related]
22. Mcl-1 ubiquitination: unique regulation of an essential survival protein.
Mojsa B; Lassot I; Desagher S
Cells; 2014 May; 3(2):418-37. PubMed ID: 24814761
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
25. BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
Habata S; Iwasaki M; Sugio A; Suzuki M; Tamate M; Satohisa S; Tanaka R; Saito T
Int J Oncol; 2016 Jul; 49(1):402-10. PubMed ID: 27120977
[TBL] [Abstract][Full Text] [Related]
26. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
Rudner J; Ruiner CE; Handrick R; Eibl HJ; Belka C; Jendrossek V
Radiat Oncol; 2010 Nov; 5():108. PubMed ID: 21080918
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma.
Potu H; Kandarpa M; Peterson LF; Durham A; Donato NJ; Talpaz M
Oncotarget; 2021 Feb; 12(3):160-172. PubMed ID: 33613844
[TBL] [Abstract][Full Text] [Related]
28. Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.
Zhou M; Wang T; Lai H; Zhao X; Yu Q; Zhou J; Yang Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):333-339. PubMed ID: 25735983
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of USP9X reverses cisplatin resistance by decreasing β-catenin expression in nasopharyngeal carcinoma cells.
Lu WX; Gan GS; Yang B
Neoplasma; 2021 Jul; 68(4):810-822. PubMed ID: 34097426
[TBL] [Abstract][Full Text] [Related]
31. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.
Schwickart M; Huang X; Lill JR; Liu J; Ferrando R; French DM; Maecker H; O'Rourke K; Bazan F; Eastham-Anderson J; Yue P; Dornan D; Huang DC; Dixit VM
Nature; 2010 Jan; 463(7277):103-7. PubMed ID: 20023629
[TBL] [Abstract][Full Text] [Related]
32. Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Lu Q; Lu D; Shao ZM; Li DQ
Cancer Sci; 2019 Apr; 110(4):1268-1278. PubMed ID: 30689267
[TBL] [Abstract][Full Text] [Related]
33. The deubiquitinase USP9X regulates FBW7 stability and suppresses colorectal cancer.
Khan OM; Carvalho J; Spencer-Dene B; Mitter R; Frith D; Snijders AP; Wood SA; Behrens A
J Clin Invest; 2018 Apr; 128(4):1326-1337. PubMed ID: 29346117
[TBL] [Abstract][Full Text] [Related]
34. Deubiquitinase USP9X deubiquitinates β-catenin and promotes high grade glioma cell growth.
Yang B; Zhang S; Wang Z; Yang C; Ouyang W; Zhou F; Zhou Y; Xie C
Oncotarget; 2016 Nov; 7(48):79515-79525. PubMed ID: 27783990
[TBL] [Abstract][Full Text] [Related]
35. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.
Cavarretta IT; Neuwirt H; Untergasser G; Moser PL; Zaki MH; Steiner H; Rumpold H; Fuchs D; Hobisch A; Nemeth JA; Culig Z
Oncogene; 2007 May; 26(20):2822-32. PubMed ID: 17072336
[TBL] [Abstract][Full Text] [Related]
36. Circ-USP9X interacts with EIF4A3 to promote endothelial cell pyroptosis by regulating GSDMD stability in atherosclerosis.
Xu S; Ge Y; Wang X; Yin W; Zhu X; Wang J; Qiao S
Clin Exp Hypertens; 2023 Dec; 45(1):2186319. PubMed ID: 36890708
[TBL] [Abstract][Full Text] [Related]
37. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
[TBL] [Abstract][Full Text] [Related]
38. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.
Cavarretta IT; Neuwirt H; Zaki MH; Steiner H; Hobisch A; Nemeth JA; Culig Z
Adv Exp Med Biol; 2008; 617():547-55. PubMed ID: 18497081
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
Zhang C; Cai TY; Zhu H; Yang LQ; Jiang H; Dong XW; Hu YZ; Lin NM; He QJ; Yang B
Mol Cancer Ther; 2011 Jul; 10(7):1264-75. PubMed ID: 21566062
[TBL] [Abstract][Full Text] [Related]
40. MCL-1 Is a Key Antiapoptotic Protein in Human and Rodent Pancreatic β-Cells.
Meyerovich K; Violato NM; Fukaya M; Dirix V; Pachera N; Marselli L; Marchetti P; Strasser A; Eizirik DL; Cardozo AK
Diabetes; 2017 Sep; 66(9):2446-2458. PubMed ID: 28667119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
